Who are Allisartan Isoproxil/Sustained-Release Indapamide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Azilsartan medoxomil and chlorthalidone, Azilsartan medoxomil - chlorthalidone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/allisartan-isoproxil-sustained-release-indapamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Allisartan Isoproxil/Sustained-Release Indapamide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allisartan Isoproxil/Sustained-Release Indapamide (Allisartan Isoproxil/Sustained-Release Indapamide) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker / Thiazide-like diuretic combination. Area: Cardiovascular.

phase 3 Angiotensin II receptor blocker / Thiazide-like diuretic combination Angiotensin II type 1 receptor (AT1R) / Sodium-chloride cotransporter (NCC) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Allisartan Isoproxil/Sustained-Release Indapamide (Allisartan Isoproxil/Sustained-Release Indapamide) — Shenzhen Salubris Pharmaceuticals Co., Ltd.. This combination drug lowers blood pressure by blocking angiotensin II receptors (allisartan isoproxil) and inhibiting sodium reabsorption in the kidney (sustained-release indapamide).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Allisartan Isoproxil/Sustained-Release Indapamide TARGET	Allisartan Isoproxil/Sustained-Release Indapamide	Shenzhen Salubris Pharmaceuticals Co., Ltd.	phase 3	Angiotensin II receptor blocker / Thiazide-like diuretic combination	Angiotensin II type 1 receptor (AT1R) / Sodium-chloride cotransporter (NCC)
Azilsartan medoxomil and chlorthalidone	Azilsartan medoxomil and chlorthalidone	Takeda	phase 3	Angiotensin II receptor blocker / Thiazide-like diuretic combination	AT1 receptor (angiotensin II type 1 receptor) / Sodium-chloride cotransporter
Azilsartan medoxomil - chlorthalidone	Azilsartan medoxomil - chlorthalidone	Takeda	phase 3	Angiotensin II receptor blocker / Thiazide-like diuretic combination	AT1 receptor (angiotensin II type 1 receptor) / Sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker / Thiazide-like diuretic combination class)

Takeda · 2 drugs in this class
Shenzhen Salubris Pharmaceuticals Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Allisartan Isoproxil/Sustained-Release Indapamide — Competitive Intelligence Brief. https://druglandscape.com/ci/allisartan-isoproxil-sustained-release-indapamide. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab